In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
Removing the roadblocks: Policies to improve access to long-acting reversible contraceptives (LARCs)
A variety of contraceptive options exist, each with their own pros and cons. Long-acting reversible contraceptives (LARCs), like IUDs, contraceptive...